Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924923 · ClinicalTrials.gov registry record
New Biopsy Technique for Uveal Melanoma
A clinical trial of Uveal Melanoma, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT01924923: Completed study of Uveal Melanoma, sponsored by Greater Houston Retina Research.
NCT01924923 is a study of Uveal Melanoma that has completed, run by Greater Houston Retina Research. The registered enrollment target is 1 participants, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924923, a study of Uveal Melanoma, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.
Conditions Studied
Study Locations (1)
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-03 |
What the finished NCT01924923 record still lists
NCT01924923 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT01924923 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01924923 about?
NCT01924923 is a clinical study titled "New Biopsy Technique for Uveal Melanoma". This pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.
What is the current status of trial NCT01924923?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2013-06. Estimated completion is 2015-03.
What conditions does trial NCT01924923 study?
This clinical trial studies the following conditions: Uveal Melanoma.
Who is sponsoring clinical trial NCT01924923?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01924923 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01924923's enrollment target sits among peer trials
1 30th of 29 the lowest of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia